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Therapy-related myeloid neoplasms (t-MN) include myelodys-
plastic syndromes (MDS) and acute myeloid leukemias (AML)
occurring as a late effect of chemotherapy and/or radiotherapy for
a primary malignancy or for autoimmune diseases.1–2 The
incidence of this complication has been raising in the past years
because of the prolonged survival and the higher number of
treated patients. Still, o5% of patients exposed to cytotoxic drugs
and radiotherapy develop a t-MN, suggesting an underlying
individual susceptibility. Primary malignancies most frequently
associated to t-MN are breast cancer and lymphoproliferative
diseases. Other recurrent clinical characteristics are presence of
multiple primary neoplasms in the same individual and cancer
familiarity.2 So far, higher frequency of single-nucleotide variants
of detoxiﬁcation and DNA-repair enzymes, alone or in association,
have been reported in t-MN, but none has been validated as
signiﬁcant risk factor in large patient groups.3–6
The association of breast and other cancers to myeloid
neoplasms is frequent in Fanconi anemia (FA), a childhood
syndrome characterized by chromosomal instability, developmental
abnormalities, aplastic anemia and by predisposition to cancer,
particularly gynecological, head-neck and gastrointestinal.7-9 FA is
associated to the occurrence of bi-allelic loss-of-function muta-
tions in the family of FANC genes, comprising 16 DNA-repair
genes. Mutations in FANCA, FANCC and FANCG are the most
common, and account for ~ 85% of the FA patients. Less than 5%
of FA patients do not appear to have mutations in these 16 genes,
indicating that additional genes may be involved. Carriers of
germline homozygous mutations of at least ﬁve of the sixteen
FA genes, including FANCD1/BRCA2, FANCJ/BRIP1, FANCN/PALB2,
FANCO/RAD51C and FANCQ/ERCC4, are at a higher-risk to develop
cancer.
So far, mutations in FA genes have been rarely described in
hematological malignancies outside the syndromic picture of
FA.10–12 We were interested in the prevalence of FA variants in
t-MN following cytotoxic treatment for breast cancer and
lymphoproliferative diseases, compared with de novo acute
myeloid leukemia (dnAML).
We studied 37 patients with a t-MN, diagnosed at our
Department of Hematology between November 1995 and January
2012. Table 1 shows patient characteristics. Median age was 63
years (range 30–78). According to the proportion of blasts, there
were 19 t-MDS and 18 t-AML. Cytogenetic analysis of bone
marrow mononuclear cells obtained at t-MN diagnosis revealed
clonal aberrations in 24 out of 32 available samples (75%). The
primary malignancy was Hodgkin lymphoma in 7 patients, non-
Hodgkin lymphoma in 12 patients and breast cancer in 18 patients
(associated with a second malignancy in ﬁve patients). As a
control, 24 dnAML patients, of a median age of 61 years (range
40–78 years), were studied at the Istituto Seragnoli of the
University of Bologna. Patients gave informed consent to the
study and the protocol received approval from the local Ethical
Committees.
Bone marrow mononuclear cells were separated at the time of
initial t-MN diagnosis using Ficoll Gradient centrifugation (Cedar-
lane, ON, Canada), and DNA was extracted by using the QIAamp
DNA Mini Kit (Qiagen AG, Hilden, Germany). DNA extracted from
different tissues of the same individuals served as germline
controls and included: lymphnode biopsies or breast specimens
(neoplastic and non-neoplastic) collected at the time of the
primary cancer diagnosis, buccal brush cytology or hair follicles
collected at the time of t-MN or dnAML diagnosis, peripheral
blood or bone marrow samples collected during follow-up of the
primary malignancy or at the time of complete remission.
We selected 14 Fanconi pathway genes (FANCD1 (BRCA2), FANCJ
(BRIP1, BACH1), FANC1, FANCA, FANCB, FANCC, FANCD2, FANCE,
FANCF, FANCG (XRCC9), FANCL (PHF9), FANCM, FANCN (PALB2) and
RAD51C). For t-MN, targeted gene enrichment was performed
using the Agilent HaloPlex system (Agilent Technologies Inc, Santa
Clara, CA, USA). Brieﬂy, following digestion of genomic DNA
samples in eight different restriction reactions, each containing
two restriction enzymes, we created a library of gDNA restriction
fragments. The collection of gDNA restriction fragments was then
Table 1. Patient characteristics
Patient characteristics n (range)
Median age (years, median, range) 63 (30–78)
Sex (M/F) 9/28
Type of t-MN according to the WHO
AML 18
MDS 19
RA 6
RAEB-1 4
RAEB-2 9
Primary malignancy
Hodgkin lymphoma 7
Non-Hodgkin lymphoma 12
Breast cancer 13
Breast and another cancer 5
Karyotype (n = 32 pts)
Normal 8
Complex 11
Isolated Chr. 7 abnorm. 4
Chr. 5+Chr. 7 abnorm. 3
11q23 1
Balanced translocation 2
Other 3
Treatment for primary malignancy
CHT 23
RT 1
RT+CHT 13
Median latency between primary cytotoxic
therapy and t-MN diagnosis (years)
6 (1.3–32.5)
Median overall survival (months) 8 (0.1–88)
Abbreviations: AML, acute myeloid leukemias; CHT, chemotherapy; MDS,
myelodysplastic syndromes; RA, refractory anemia; RT, radiotherapy.
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hybridized to the HaloPlex probe capture library. During the
hybridization process, Illumina (San Diego, CA, USA) sequencing
motifs including index sequences were incorporated into the
targeted fragments. The circularized target DNA-HaloPlex probe
hybrids, containing biotin, captured on streptavidin beads were
then ligated using a DNA ligase to close nicks in the circularized
HaloPlex probe-target DNA hybrids. The captured target DNA was
then eluted with NaOH and ampliﬁed by PCR. The ampliﬁed target
DNA was puriﬁed using AMPure XP beads (Beckman Coulter Inc,
High Wycombe, UK), validated and quantiﬁed by microﬂuidics
analysis using the 2100 Bioanalyzer (Agilent Technologies).
Samples have been pooled with different indexes for multiplexed
sequencing using Illumina Hiseq platform at the Cancer and Stem
Cell Biology, Duke-NUS Graduate Medical School in Singapore.
Sequencing data were aligned to hg19 using the Burrows-Wheeler
Aligner software. Variants were called using the Genome Analysis
Toolkit (GATK, v1.0.4333; Beckman Coulter Inc). dnAML samples
were studied using 100 bp paired-end whole-exome-sequencing
(HiSeq2000, Illumina). Variants were called with the Genome
Analysis Toolkit (GATK).
Variants detected by NGS were conﬁrmed by pyrosequencing
or Sanger sequencing, using speciﬁcally designed oligonucletides
targeting the mutated region (Supplementary Table 1). Reagents
and conditions were as recommended by the manufacturers
(PyroMark Q96 ID, Diatech Pharmacogenetics, Jesi, Italy). A BLAST
search on NCBI, Cosmic and UCSC databases was performed for all
identiﬁed variants. The Polyphen-2 tool (genetics.bwh.harvard.
edu) was consulted to deﬁne the putative effect of FA discovered
variants, predicting the possible impact of the amino acid
substitutions on the structure and function of the proteins. Odds
ratios, with 95% conﬁdence interval were also calculated.
FA gene variants were frequent in our t-MN patients, with 6 out
of 37 patients (16%) carriers of at least one genomic variant, with
similar prevalence in t-MN secondary to lymphoproliferative
diseases versus solid tumors (4 out of 19 vs 2 out of 18,
respectively). We found seven heterozygous FANC variants,
including two FANCA (L6F and S90T), three FANCD2 (T1376A,
P256S and M1023V), one FANCJ (I364V) and one FANCC (L36F)
(Table 2). There were no differences in the time between primary
cytotoxic treatment and t-MN diagnosis in carriers of FA variant
versus wild-type patients (median, 72 vs 69 months). Six variants
were novel, according to the NCBI and Cosmic databases, whereas
the FANCA L6F had been previously described in the 1000
Genome project (www.1000genomes.org) and reported in the
UCSC Genome Browser in the transcript variant 2 of FANCA mRNA
(uc002fow.1). This same variation has been conﬂictually reported
as SNV in the 5ʹ UTR of NCBI Reference Assembly (rs189841793).
To determine whether FANC genetic variants were somatically
acquired in t-MN patients, germline material was screened in ﬁve
patients for whom control tissues were available. The FANC mutation
was germline in all cases (5 conﬁrmed in 37 t-MN patients, 13.5%)
(Table 2). As a control, the frequency of FANC variant in t-MN was
compared with that of 24 dnAML patients, studied using whole-
exome-sequencing. We found that 3 out of 24 patients (12.5%) were
carriers of a germline FA variant (1 FANCA, 1 FANCL and 1 FANCJ). This
translates into a similar prevalence of FA SNV in t-MN and dnAML.
Since SNV in FA genes seem frequent both in dnAML and in t-MN, we
suggest that these variants may have a role as risk factors in the
development of myeloid neoplasms.
As all FANC variants were novel, further studies will be necessary
to clarify the functional impact of these variants on the gene product
and DNA damage repair. According to the Polyphen-2 database
(genetics.bwh.harvard.edu) ﬁve out of eight FA variants were deﬁned
probably or possibly damaging DNA repair (Supplementary Table 2).
Functional studies using constructs including the mutated sequences
may help to answer this question.13
Our data may indicate that heterozygous carriers of FA variants
may have increased susceptibility to environmental carcinogens
and to the DNA-damaging action of cytotoxic therapy used to
treat primary tumors, leading to de novo or secondary leukemo-
genesis. In this line, a trend towards higher DEB-induced
chromosome breakage and an increased release of fragmented
DNA after exposure to X-irradiation have been reported in FA
heterozygotes relative to controls.14
We have previously reported that t-MN secondary to lympho-
proliferative diseases were characterized by a very low frequency
or absence of epigenetic and spliceosome gene mutations,
compared to t-MN following solid tumors.15 As the frequency of
FA germline variants in this study did not appear to be different
between lymphoproliferative neoplasms and breast cancer and
between de novo and t-MN, the probable functional role of these
variants in carcinogenesis does not appear to be restricted to a
speciﬁc type of primary cancer or its treatment.
In the near future, we might have to revise our concept of
genetic susceptibility to AML, taking into account not only
recurrent genetic variants, such as polymorphisms, but also rare
individual germline variants in critical genes.
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Table 2. Characteristics of t-MN patients carriers of FANC variants
UPN Primary tumor, age t-MN latency, karyotype Gene symbol and
AA change
NCBI rs and/or
COSMIC numbers
Control tissue
6531 Breast, 57 years 72 months, del5q31 FANCA L6F rs189841793 Breast cancer and normal breast tissue
3155 NHL, 69 years 66 months, complex FANCA S90T Novel NHL biopsy
5993 HL, thyroid, 52 years 48 months, Del7 FANCD2 T1376A Novel HL biopsy and normal lymphnode
6190 HL, 47 years 208 months, Trisomy 8 FANCD2 P256S Novel Buccal swab and hair follicle
6828 HL, 60 years 112 months, n.a. FANCD2 M1023V; Novel HL biopsy
2885 Breast/ adrenal, na na FANCJ I364V FANCC L36F Novel Not available
Abbreviations: HL, Hodgkin lymphoma; NHL, Non-Hodgkin lymphoma; t-MN, therapy-related myeloid neoplasms. NCBI and Cosmic database variant number
and the reported frequency is indicated.
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